Compare · FMS vs SHC
FMS vs SHC
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Sotera Health Company (SHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and SHC operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.31B, about 2.8x SHC ($4.45B).
- Over the past year, FMS is down 23.1% and SHC is up 26.9% - SHC leads by 50.1 points.
- SHC has been more active in the news (16 items in the past 4 weeks vs 9 for FMS).
- SHC has more recent analyst coverage (25 ratings vs 21 for FMS).
- Company
- Fresenius Medical Care AG
- Sotera Health Company
- Price
- $22.02+0.41%
- $15.63+0.35%
- Market cap
- $12.31B
- $4.45B
- 1M return
- +4.78%
- -0.98%
- 1Y return
- -23.15%
- +26.91%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 16
- Recent ratings
- 21
- 25
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Latest FMS
- Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
- SEC Form SD filed by Fresenius Medical Care AG
- Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
- Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
- Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
- SEC Form 6-K filed by Fresenius Medical Care AG
Latest SHC
- Goldman initiated coverage on Sotera Health with a new price target
- SEC Form SD filed by Sotera Health Company
- Director Klee Ann R. was granted 14,970 shares, increasing direct ownership by 12% to 140,926 units (SEC Form 4)
- Chief Executive Officer Shader Alton was granted 579,573 shares (SEC Form 4)
- SEC Form 3 filed by new insider Shader Alton
- Director Kyle Richard G was granted 14,970 shares (SEC Form 4)
- Director Krause Kenneth D. was granted 14,970 shares (SEC Form 4)
- Director Cunningham Sean Laurence was granted 14,970 shares, increasing direct ownership by 19% to 95,751 units (SEC Form 4)
- Director Flynn Karen was granted 14,970 shares, increasing direct ownership by 38% to 54,191 units (SEC Form 4)
- Director Neary James was granted 14,970 shares, increasing direct ownership by 19% to 95,751 units (SEC Form 4)